In conclusions, the expression of CCND1 and ER activity following neoadjuvant endocrine therapy may be associated with the efficacy of chemo-endocrine therapy in post-menopausal patients with ER-positive and HER2-negative breast cancer. This evidence concerns the gene ESR1 and breast cancer.